Triple Therapy for HER2-Positive Gastric Cancer Shrinks Tumors

The addition of pembrolizumab (Keytruda) to trastuzumab (Herceptin) and platinum-based chemotherapy led to a significant improvement in overall response rate.

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Netherlands ,Amsterdam ,Noord Holland ,American ,Merck Serono ,Yelena Janjigian ,Genentech Roche ,Eli Lilly ,Myriam Chalabi ,Bristol Myers Squibb ,Pfizer ,Astrazeneca ,American Society Of Clinical Oncology ,Netherlands Cancer Institute ,American Society ,Clinical Oncology ,Merck Sharp ,Basilea Pharmaceutical ,Noncolorectal Gastrointestinal Cancer ,Oncolorectal Gi Cancer ,Cancer ,Alignant Neoplasia ,Arcinoma ,Neoplasm ,Tumor ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Gastric Cancer ,Alignant Stomach Neoplasm ,Chemotherapy ,Adenocarcinoma Gastroesophageal Junction ,Biologic Therapy ,Immunotherapy ,Platinum ,